Johnson & Johnson has come out fighting after Pfizer announced yesterday that it is ready to launch a biosimilar competitor to its blockbuster Remicade. J&J said it had a “biosimilar ...

possible malignancies and hepatitis B reactivation Infliximab (Remicade®) Infusion reactions and upper respiratory infections Serious bacterial infections, unusual infections (tuberculosis and ...

Rebetol The EU has approved a new indication for infliximab injection (Remicade), gadofosveset trisodium injection (Vasovist), and a new indication for a 24-week regimen for peginterferon alfa-2b ...